<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00412113</url>
  </required_header>
  <id_info>
    <org_study_id>A3841045</org_study_id>
    <nct_id>NCT00412113</nct_id>
  </id_info>
  <brief_title>A Multi-Risk Factor Strategy vs a Guideline-Based Approach in Achieving Blood Pressure and Lipid Goals in Hypertensives at Extra Risk</brief_title>
  <acronym>TOGETHER</acronym>
  <official_title>A 6-Week, Prospective, Randomized, Double-Blind, Double-Dummy Phase IV Clinical Trial Designed to Evaluate the Efficacy of an Aggressive Multi-Risk Factor Management Strategy With Caduet (A3841045) Versus a Guideline-Based Approach in Achieving Blood Pressure and Lipid Goals in Hypertensive Subjects With Additional Risk Factors.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate whether an aggressive multi-risk factor
      management strategy (Caduet plus therapeutic lifestyle changes (TLC) regimen) will result in
      greater percentage of patients achieving blood pressure and low density lipoprotein
      cholesterol (LDL-C) goals compared with a Joint National Committee 7/ National Cholesterol
      Education Program Adult Treatment Panel III (JNC 7/NCEP ATP III) guideline-based approach
      (Norvasc plus TLC regimen) after 6 weeks of treatment in primary prevention subjects with
      hypertension and additional risk factors, including dyslipidemia.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2007</start_date>
  <completion_date type="Actual">April 2008</completion_date>
  <primary_completion_date type="Actual">April 2008</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Subjects With Blood Pressure (BP) &lt;140/90 Millimeters of Mercury (mmHg) and Low Density Lipoprotein Cholesterol (LDL-C) &lt;100 Milligrams Per Deciliter(mg/dL) at Week 6</measure>
    <time_frame>Week 6</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline to Week 6 in Framingham Predicted Absolute 10-year Risk</measure>
    <time_frame>Week 6, baseline</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Subjects With Blood Pressure of &lt;140/90 mmHg and LDL-C &lt;100 mg/dL at Week 4</measure>
    <time_frame>Week 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subjects With BP &lt;140/90 mmHg and LDL-C &lt;130 mg/dL at Week 4.</measure>
    <time_frame>Week 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subjects With BP &lt;140/90 mmHg and LDL-C &lt;130 mg/dL at Week 6.</measure>
    <time_frame>Week 6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subjects With LDL-C &lt; 100 mg/dL at Week 4</measure>
    <time_frame>Week 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subjects With LDL-C &lt; 100 mg/dL at Week 6</measure>
    <time_frame>Week 6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subjects With BP &lt; 140/90 mmHg at Week 4</measure>
    <time_frame>Week 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subjects With BP &lt; 140/90 mmHg at Week 6</measure>
    <time_frame>Week 6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Week 4 in Systolic Blood Pressure (SBP).</measure>
    <time_frame>Week 4, baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Week 4 in Diastolic Blood Pressure (DBP)</measure>
    <time_frame>Week 4, baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Week 4 in Pulse Rate</measure>
    <time_frame>Week 4, baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Week 6 in Systolic Blood Pressure (SBP)</measure>
    <time_frame>Week 6, baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Week 6 in Diastolic Blood Pressue (DBP)</measure>
    <time_frame>Week 6, baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Week 6 in Pulse Rate</measure>
    <time_frame>Week 6, baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in LDL at Week 4.</measure>
    <time_frame>Week 4, baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in High Density Lipoprotein (HDL) at Week 4.</measure>
    <time_frame>Week 4, baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Total Cholesterol (TC) From Baseline to Week 4.</measure>
    <time_frame>Week 4, baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Triglycerides (TG) to Week 4.</measure>
    <time_frame>Week 4, baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in LDL at Week 6.</measure>
    <time_frame>Week 6, baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in HDL at Week 6.</measure>
    <time_frame>Week 6, baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Total Cholesterol (TC) to Week 6.</measure>
    <time_frame>Week 6, baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Triglycerides (TG) at Week 6.</measure>
    <time_frame>Week 6 , baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Week 4 in Framingham Predicted Absolute 10-year Risk.</measure>
    <time_frame>Week 4, baseline</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">245</enrollment>
  <condition>Dyslipidemia</condition>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>Norvasc 5 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Blinded amlodipine 5 mg and amlodipine/atorvastatin single pill combination 5/20 mg placebo dosed once daily for 6 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Caduet 10/20mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Blinded amlodipine/atorvastatin single pill combination 10/20 mg dosed once daily for 6 weeks and amlodipine besylate 10 mg placebo.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Norvasc 10 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Blinded amlodipine 19 mg and amlodipine/atorvastatin single pill combination 10/20 mg placebo dosed once daily for 6 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Caduet 5/20mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Blinded amlodipine/atorvastatin single pill combination 5/20 mg and amlodipine besylate 5 mg placebo dosed once daily for 6 weeks .</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Amlodipine besylate</intervention_name>
    <description>Amlodipine besylate 5 mg</description>
    <arm_group_label>Norvasc 5 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Amlodipine besylate/atorvastatin calcium single pill combination</intervention_name>
    <description>Amlodipine/atorvastatin single pill combination 10/20 mg</description>
    <arm_group_label>Caduet 10/20mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Amlodipine besylate</intervention_name>
    <description>Amlodipine besylate 10 mg</description>
    <arm_group_label>Norvasc 10 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Amlodipine besylate/atorvastatin calcium single pill combination</intervention_name>
    <description>Amlodipine/atorvastatin single pill combination 5/20 mg</description>
    <arm_group_label>Caduet 5/20mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects with diagnosed hypertension receiving treatment with Norvasc 5 or 10 mg and
             who also have 3 additional cardiovascular risk factors, including dyslipidemia.

        Exclusion Criteria:

          -  Subjects who are taking the following prohibited medications within 14 days of
             screening: lipid-lowering therapy, calcium channel blocker other then Norvasc, &gt;3
             antihypertensive agents (including Norvasc)

          -  Subjects that have not been on a stable dose of Norvasc for at least 4 weeks

          -  Subjects with a history of coronary heart disease, stroke, or Pulmonary Vascular
             Disease (PVD)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35216</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35234</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Mesa</city>
        <state>Arizona</state>
        <zip>85206</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Garden Grove</city>
        <state>California</state>
        <zip>92843</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Mission Viejo</city>
        <state>California</state>
        <zip>92692</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Rancho Santa Margarita</city>
        <state>California</state>
        <zip>92688</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Torrance</city>
        <state>California</state>
        <zip>90502</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32605</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Kissimmee</city>
        <state>Florida</state>
        <zip>34741</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Melbourne</city>
        <state>Florida</state>
        <zip>32935</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33176</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Safety Harbor</city>
        <state>Florida</state>
        <zip>34695</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>St. Petersburg</city>
        <state>Florida</state>
        <zip>33701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Augusta</city>
        <state>Georgia</state>
        <zip>30904</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Tucker</city>
        <state>Georgia</state>
        <zip>30084</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>South Bend</city>
        <state>Indiana</state>
        <zip>46601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Erlanger</city>
        <state>Kentucky</state>
        <zip>41018</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Auburn</city>
        <state>Maine</state>
        <zip>04210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Warren</city>
        <state>Michigan</state>
        <zip>48091</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Chesterfield</city>
        <state>Missouri</state>
        <zip>63017</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Florissant</city>
        <state>Missouri</state>
        <zip>63031</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68116-2004</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Henderson</city>
        <state>Nevada</state>
        <zip>89014</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Henderson</city>
        <state>Nevada</state>
        <zip>89015</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Belvidere</city>
        <state>New Jersey</state>
        <zip>07823</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Bridgewater</city>
        <state>New Jersey</state>
        <zip>08807</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Clifton</city>
        <state>New Jersey</state>
        <zip>07013</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Elizabeth</city>
        <state>New Jersey</state>
        <zip>07202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Hillsborough</city>
        <state>New Jersey</state>
        <zip>08844</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Trenton</city>
        <state>New Jersey</state>
        <zip>08618</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Brooklyn</city>
        <state>New York</state>
        <zip>11229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45219</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45242</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Tulsa</city>
        <state>Oklahoma</state>
        <zip>74136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Bensalem</city>
        <state>Pennsylvania</state>
        <zip>19020</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Lansdale</city>
        <state>Pennsylvania</state>
        <zip>19446</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19146</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02904</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Goose Creek</city>
        <state>South Carolina</state>
        <zip>29445</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Mount Pleasant</city>
        <state>South Carolina</state>
        <zip>29464</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Bristol</city>
        <state>Tennessee</state>
        <zip>37620</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Kingsport</city>
        <state>Tennessee</state>
        <zip>37660</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75235</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030-2324</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Plano</city>
        <state>Texas</state>
        <zip>75093</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78238</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Chesapeake</city>
        <state>Virginia</state>
        <zip>23320</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=A3841045&amp;StudyName=A%20Multi-Risk%20Factor%20Strategy%20Vs%20A%20Guideline-Based%20Approach%20In%20Achieving%20Blood%20Pressure%20%26%20Lipid%20Goals%20In%20Hypertensives%20At%20Extra%20Risk</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>March 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 13, 2006</study_first_submitted>
  <study_first_submitted_qc>December 13, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 15, 2006</study_first_posted>
  <results_first_submitted>April 13, 2009</results_first_submitted>
  <results_first_submitted_qc>September 29, 2009</results_first_submitted_qc>
  <results_first_posted type="Estimate">November 6, 2009</results_first_posted>
  <last_update_submitted>November 12, 2009</last_update_submitted>
  <last_update_submitted_qc>November 12, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 20, 2009</last_update_posted>
  <responsible_party>
    <name_title>Director, Clinical Trial Disclosure Group</name_title>
    <organization>Pfizer, Inc.</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dyslipidemias</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Calcium, Dietary</mesh_term>
    <mesh_term>Atorvastatin Calcium</mesh_term>
    <mesh_term>Amlodipine, atorvastatin drug combination</mesh_term>
    <mesh_term>Amlodipine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>The study enrolled 244 evaluable subjects. Drug treatments were used prior to the start of the study in all subjects in the Caduet and therapeutic lifestyle changes (TLC) group and the Norvasc and TLC group. Amlodipine was used by all subjects prior to entry. The study's four arms are two groups, each with drug group and matching placebo.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Norvasc + TLC</title>
          <description>Blinded Norvasc (amlodipine) 5 to 10 milligram (mg) and matching Caduet placebo dosed once daily along with Therapeutic Lifestyle Changes (TLC) for 6 weeks.</description>
        </group>
        <group group_id="P2">
          <title>Caduet + TLC</title>
          <description>Blinded Caduet (amlodipine besylate/atorvastatin calcium) 5/20 to 10/20 mg and matching Norvasc placebo dosed once daily along with TLC for 6 weeks.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="123">15-January-2007</participants>
                <participants group_id="P2" count="122">15-January-2007</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received Treatment</title>
              <participants_list>
                <participants group_id="P1" count="122">One subject assigned to Norvasc and TLC did not receive treatment and was excluded from all analyses</participants>
                <participants group_id="P2" count="122"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="111">15-April-2008</participants>
                <participants group_id="P2" count="107">15-April-2008</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="15"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="15"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>did not receive treatment</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Norvasc + TLC</title>
          <description>Blinded Norvasc (amlodipine) 5 to 10 milligram (mg) and matching Caduet placebo dosed once daily along with Therapeutic Lifestyle Changes (TLC) for 6 weeks.</description>
        </group>
        <group group_id="B2">
          <title>Caduet + TLC</title>
          <description>Blinded Caduet (amlodipine besylate/atorvastatin calcium) 5/20 to 10/20 mg and matching Norvasc placebo dosed once daily along with TLC for 6 weeks.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="122"/>
            <count group_id="B2" value="122"/>
            <count group_id="B3" value="244"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>18 to 64 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="95"/>
                    <measurement group_id="B2" value="97"/>
                    <measurement group_id="B3" value="192"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt; or = to 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                    <measurement group_id="B2" value="25"/>
                    <measurement group_id="B3" value="52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="56"/>
                    <measurement group_id="B2" value="65"/>
                    <measurement group_id="B3" value="121.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="66"/>
                    <measurement group_id="B2" value="57"/>
                    <measurement group_id="B3" value="123.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Subjects With Blood Pressure (BP) &lt;140/90 Millimeters of Mercury (mmHg) and Low Density Lipoprotein Cholesterol (LDL-C) &lt;100 Milligrams Per Deciliter(mg/dL) at Week 6</title>
        <description>Number of subjects reaching dual goal of systolic blood pressure &lt;140 millimeters of mercury (mmHg) and diastolic blood pressue of &lt;90 mmHg and low density lipoprotein-cholesterol(LDL-C) &lt;100 milligrams per deciliter(mg/dL)</description>
        <time_frame>Week 6</time_frame>
        <population>Full analysis set (FAS) is all randomized subjects who take at least one dose of study drug and and have any post-baseline efficacy assessments.</population>
        <group_list>
          <group group_id="O1">
            <title>Norvasc + TLC</title>
            <description>Blinded Norvasc (amlodipine) 5 to 10 milligram (mg) and matching Caduet placebo dosed once daily along with Therapeutic Lifestyle Changes (TLC) for 6 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Caduet + TLC</title>
            <description>Blinded Caduet (amlodipine besylate/atorvastatin calcium) 5/20 to 10/20 mg and matching Norvasc placebo dosed once daily along with TLC for 6 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Subjects With Blood Pressure (BP) &lt;140/90 Millimeters of Mercury (mmHg) and Low Density Lipoprotein Cholesterol (LDL-C) &lt;100 Milligrams Per Deciliter(mg/dL) at Week 6</title>
          <description>Number of subjects reaching dual goal of systolic blood pressure &lt;140 millimeters of mercury (mmHg) and diastolic blood pressue of &lt;90 mmHg and low density lipoprotein-cholesterol(LDL-C) &lt;100 milligrams per deciliter(mg/dL)</description>
          <population>Full analysis set (FAS) is all randomized subjects who take at least one dose of study drug and and have any post-baseline efficacy assessments.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="115"/>
                <count group_id="O2" value="118"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Null hypothesis: There is no difference between the two treatment management strategies in the percentage of patients achieving both the BP(&lt; 140/90 mmHg) and LDL goal (&lt; 100mg/dL) at Week 6.
With ~120 in each treatment arm, planned power was at least 90% to detect a difference between treatments, assuming 35% in the Caduet and 15% in the Norvasc arm achieving BP &lt;140/90 mmHg and LDL &lt;100 mg/dL and using a chi-square test with 0.05 two-sided significance level.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>There was only one primary endpoint and the p-value was not adjusted for comparison.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>19.03</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>9.14</ci_lower_limit>
            <ci_upper_limit>39.63</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Subjects With Blood Pressure of &lt;140/90 mmHg and LDL-C &lt;100 mg/dL at Week 4</title>
        <description>Subjects achieving both the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC)-7 blood pressure goal of &lt;140/90 mmHg and the National Cholesterol Education Program Adult Treatment Panel (NCEP/ATP) III Update low density lipoprotein-cholesterol (LDL-C) goal &lt;100 mg/dL at Week 4.</description>
        <time_frame>Week 4</time_frame>
        <population>Full analysis set. All randomized subjects who took study drug and had at least one post-baseline efficacy assessment comprised the FAS.</population>
        <group_list>
          <group group_id="O1">
            <title>Norvasc + TLC</title>
            <description>Blinded Norvasc (amlodipine) 5 to 10 milligram (mg) and matching Caduet placebo dosed once daily along with Therapeutic Lifestyle Changes (TLC) for 6 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Caduet + TLC</title>
            <description>Blinded Caduet (amlodipine besylate/atorvastatin calcium) 5/20 to 10/20 mg and matching Norvasc placebo dosed once daily along with TLC for 6 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Subjects With Blood Pressure of &lt;140/90 mmHg and LDL-C &lt;100 mg/dL at Week 4</title>
          <description>Subjects achieving both the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC)-7 blood pressure goal of &lt;140/90 mmHg and the National Cholesterol Education Program Adult Treatment Panel (NCEP/ATP) III Update low density lipoprotein-cholesterol (LDL-C) goal &lt;100 mg/dL at Week 4.</description>
          <population>Full analysis set. All randomized subjects who took study drug and had at least one post-baseline efficacy assessment comprised the FAS.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="115"/>
                <count group_id="O2" value="116"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Null hypothesis: There is no difference between the two treatment management strategies in the percentage of patients achieving both the blood pressure (&lt; 140/90 mmHg) and LDL-goal (&lt;100 mg/dL) at Week 4.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>No adjustment for p-value for secondary analysis</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>31.39</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>12.61</ci_lower_limit>
            <ci_upper_limit>78.09</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Subjects With BP &lt;140/90 mmHg and LDL-C &lt;130 mg/dL at Week 4.</title>
        <description>Subjects achieving both JNC-7 blood pressure goal of &lt;140/90 mmHg and NCEP/ATP III LDL-C goal &lt;130 mg/dL at Week 4.</description>
        <time_frame>Week 4</time_frame>
        <population>Full analysis set (FAS). All randomized subjects who took study drug and had at least one post-baseline efficacy assessment comprised the FAS.</population>
        <group_list>
          <group group_id="O1">
            <title>Norvasc + TLC</title>
            <description>Blinded Norvasc (amlodipine) 5 to 10 milligram (mg) and matching Caduet placebo dosed once daily along with Therapeutic Lifestyle Changes (TLC) for 6 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Caduet + TLC</title>
            <description>Blinded Caduet (amlodipine besylate/atorvastatin calcium) 5/20 to 10/20 mg and matching Norvasc placebo dosed once daily along with TLC for 6 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Subjects With BP &lt;140/90 mmHg and LDL-C &lt;130 mg/dL at Week 4.</title>
          <description>Subjects achieving both JNC-7 blood pressure goal of &lt;140/90 mmHg and NCEP/ATP III LDL-C goal &lt;130 mg/dL at Week 4.</description>
          <population>Full analysis set (FAS). All randomized subjects who took study drug and had at least one post-baseline efficacy assessment comprised the FAS.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="115"/>
                <count group_id="O2" value="118"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41"/>
                    <measurement group_id="O2" value="85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Null hypothesis: There is no difference between the two treatment management strategies in the percentage of patients achieving both the blood pressure (&lt; 140/90 mmHg) and LDL-goal (&lt;130mg/dL) at Week 4.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>No adjustment for p-value for secondary analyses</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>5.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>2.93</ci_lower_limit>
            <ci_upper_limit>9.24</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Subjects With BP &lt;140/90 mmHg and LDL-C &lt;130 mg/dL at Week 6.</title>
        <description>Subjects achieving both JNC-7 blood pressure goal of &lt;140/90 mmHg and NCEP/ATP III LDL-C goal &lt;130 mg/dL at Week 6.</description>
        <time_frame>Week 6</time_frame>
        <population>Full analysis set (FAS).</population>
        <group_list>
          <group group_id="O1">
            <title>Norvasc + TLC</title>
            <description>Blinded Norvasc (amlodipine) 5 to 10 milligram (mg) and matching Caduet placebo dosed once daily along with Therapeutic Lifestyle Changes (TLC) for 6 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Caduet + TLC</title>
            <description>Blinded Caduet (amlodipine besylate/atorvastatin calcium) 5/20 to 10/20 mg and matching Norvasc placebo dosed once daily along with TLC for 6 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Subjects With BP &lt;140/90 mmHg and LDL-C &lt;130 mg/dL at Week 6.</title>
          <description>Subjects achieving both JNC-7 blood pressure goal of &lt;140/90 mmHg and NCEP/ATP III LDL-C goal &lt;130 mg/dL at Week 6.</description>
          <population>Full analysis set (FAS).</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="115"/>
                <count group_id="O2" value="118"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45"/>
                    <measurement group_id="O2" value="90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Null hypothesis: There is no difference between the two treatment management strategies in the percentage of patients achieving both the blood pressure (&lt; 140/90 mmHg) and LDL-goal (&lt;130mg/dL) at Week 6.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>No adjustment for p-value for secondary analyses</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>5.14</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>2.89</ci_lower_limit>
            <ci_upper_limit>9.11</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Subjects With LDL-C &lt; 100 mg/dL at Week 4</title>
        <description>Subjects Who achieve a goal of LDL-C &lt; 100 mg/dL at Week 4.</description>
        <time_frame>Week 4</time_frame>
        <population>Full analysis set (FAS). All randomized subjects who took study drug and had at least one post-baseline efficacy assessment comprised the FAS.</population>
        <group_list>
          <group group_id="O1">
            <title>Norvasc + TLC</title>
            <description>Blinded Norvasc (amlodipine) 5 to 10 milligram (mg) and matching Caduet placebo dosed once daily along with Therapeutic Lifestyle Changes (TLC) for 6 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Caduet + TLC</title>
            <description>Blinded Caduet (amlodipine besylate/atorvastatin calcium) 5/20 to 10/20 mg and matching Norvasc placebo dosed once daily along with TLC for 6 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Subjects With LDL-C &lt; 100 mg/dL at Week 4</title>
          <description>Subjects Who achieve a goal of LDL-C &lt; 100 mg/dL at Week 4.</description>
          <population>Full analysis set (FAS). All randomized subjects who took study drug and had at least one post-baseline efficacy assessment comprised the FAS.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="115"/>
                <count group_id="O2" value="118"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Null hypothesis: There is no difference between the two treatment management strategies in the percentage of patients achieving (&lt;100mg/DL) at Week 4.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>No adjustment for p-value for secondary analyses</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>65.51</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>27.10</ci_lower_limit>
            <ci_upper_limit>158.34</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Subjects With LDL-C &lt; 100 mg/dL at Week 6</title>
        <description>Subjects Who achieve a goal of LDL-C &lt; 100 mg/dL at Week 6.</description>
        <time_frame>Week 6</time_frame>
        <population>Full analysis set (FAS) All randomized subjects who take at least one dose of study drug and have any post-baseline efficacy assessments.</population>
        <group_list>
          <group group_id="O1">
            <title>Norvasc + TLC</title>
            <description>Blinded Norvasc (amlodipine) 5 to 10 milligram (mg) and matching Caduet placebo dosed once daily along with Therapeutic Lifestyle Changes (TLC) for 6 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Caduet + TLC</title>
            <description>Blinded Caduet (amlodipine besylate/atorvastatin calcium) 5/20 to 10/20 mg and matching Norvasc placebo dosed once daily along with TLC for 6 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Subjects With LDL-C &lt; 100 mg/dL at Week 6</title>
          <description>Subjects Who achieve a goal of LDL-C &lt; 100 mg/dL at Week 6.</description>
          <population>Full analysis set (FAS) All randomized subjects who take at least one dose of study drug and have any post-baseline efficacy assessments.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="115"/>
                <count group_id="O2" value="118"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Null hypothesis: There is no difference between the two treatment management strategies in the percentage of patients achieving LDL-goal (&lt;100mg/DL) at Week 6.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>No adjustment for p-value for secondary analyses</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>42.04</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>19.42</ci_lower_limit>
            <ci_upper_limit>90.99</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Subjects With BP &lt; 140/90 mmHg at Week 4</title>
        <description>Subjects achieving BP goal of &lt;140/90 mmHg at week 4</description>
        <time_frame>Week 4</time_frame>
        <population>Full analysis set (FAS). All randomized subjects who took study drug and had at least one post-baseline efficacy assessment comprised the FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Norvasc + TLC</title>
            <description>Blinded Norvasc (amlodipine) 5 to 10 milligram (mg) and matching Caduet placebo dosed once daily along with Therapeutic Lifestyle Changes (TLC) for 6 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Caduet + TLC</title>
            <description>Blinded Caduet (amlodipine besylate/atorvastatin calcium) 5/20 to 10/20 mg and matching Norvasc placebo dosed once daily along with TLC for 6 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Subjects With BP &lt; 140/90 mmHg at Week 4</title>
          <description>Subjects achieving BP goal of &lt;140/90 mmHg at week 4</description>
          <population>Full analysis set (FAS). All randomized subjects who took study drug and had at least one post-baseline efficacy assessment comprised the FAS</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="115"/>
                <count group_id="O2" value="117"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="84"/>
                    <measurement group_id="O2" value="87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Null hypothesis: There is no difference between the two treatment management strategies in the percentage of patients achieving blood pressure (&lt; 140/90 mmHg)at Week 4</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.785</p_value>
            <p_value_desc>No adjustment for p-value for secondary analyses</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.09</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.60</ci_lower_limit>
            <ci_upper_limit>1.98</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Subjects With BP &lt; 140/90 mmHg at Week 6</title>
        <description>Subjects achieving BP goal of &lt;140/90 mmHg at week 6</description>
        <time_frame>Week 6</time_frame>
        <population>Full analysis set (FAS) All randomized subjects who take at least one dose of study drug and have any post-baseline efficacy assessments.</population>
        <group_list>
          <group group_id="O1">
            <title>Norvasc + TLC</title>
            <description>Blinded Norvasc (amlodipine) 5 to 10 milligram (mg) and matching Caduet placebo dosed once daily along with Therapeutic Lifestyle Changes (TLC) for 6 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Caduet + TLC</title>
            <description>Blinded Caduet (amlodipine besylate/atorvastatin calcium) 5/20 to 10/20 mg and matching Norvasc placebo dosed once daily along with TLC for 6 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Subjects With BP &lt; 140/90 mmHg at Week 6</title>
          <description>Subjects achieving BP goal of &lt;140/90 mmHg at week 6</description>
          <population>Full analysis set (FAS) All randomized subjects who take at least one dose of study drug and have any post-baseline efficacy assessments.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="115"/>
                <count group_id="O2" value="118"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83"/>
                    <measurement group_id="O2" value="94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Null hypothesis: There is no difference between the two treatment management strategies in the percentage of patients achieving blood pressure (&lt; 140/90 mmHg) at Week 6.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.171</p_value>
            <p_value_desc>No adjustment for p-value for secondary analyses</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.55</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.83</ci_lower_limit>
            <ci_upper_limit>2.88</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Week 4 in Systolic Blood Pressure (SBP).</title>
        <description>Mean at observation minus mean at baseline</description>
        <time_frame>Week 4, baseline</time_frame>
        <population>Full analysis set (FAS). All randomized subjects who took study drug and had at least one post-baseline efficacy assessment comprised the FAS.</population>
        <group_list>
          <group group_id="O1">
            <title>Norvasc + TLC</title>
            <description>Blinded Norvasc (amlodipine) 5 to 10 milligram (mg) and matching Caduet placebo dosed once daily along with Therapeutic Lifestyle Changes (TLC) for 6 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Caduet + TLC</title>
            <description>Blinded Caduet (amlodipine besylate/atorvastatin calcium) 5/20 to 10/20 mg and matching Norvasc placebo dosed once daily along with TLC for 6 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Week 4 in Systolic Blood Pressure (SBP).</title>
          <description>Mean at observation minus mean at baseline</description>
          <population>Full analysis set (FAS). All randomized subjects who took study drug and had at least one post-baseline efficacy assessment comprised the FAS.</population>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="115"/>
                <count group_id="O2" value="118"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.6" spread="12.1"/>
                    <measurement group_id="O2" value="-1.5" spread="11.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Null hypothesis: There is no difference between the two treatment management strategies in the mean change from baseline in systolic blood pressure at Week 4.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.585</p_value>
            <p_value_desc>No adjustment for p-value for secondary analyses</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Difference in LS Means</param_type>
            <param_value>0.76</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-1.97</ci_lower_limit>
            <ci_upper_limit>3.48</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Week 4 in Diastolic Blood Pressure (DBP)</title>
        <description>Mean at observation minus mean at baseline</description>
        <time_frame>Week 4, baseline</time_frame>
        <population>Full analysis set (FAS). All randomized subjects who took study drug and had at least one post-baseline efficacy assessment comprised the FAS.</population>
        <group_list>
          <group group_id="O1">
            <title>Norvasc + TLC</title>
            <description>Blinded Norvasc (amlodipine) 5 to 10 milligram (mg) and matching Caduet placebo dosed once daily along with Therapeutic Lifestyle Changes (TLC) for 6 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Caduet + TLC</title>
            <description>Blinded Caduet (amlodipine besylate/atorvastatin calcium) 5/20 to 10/20 mg and matching Norvasc placebo dosed once daily along with TLC for 6 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Week 4 in Diastolic Blood Pressure (DBP)</title>
          <description>Mean at observation minus mean at baseline</description>
          <population>Full analysis set (FAS). All randomized subjects who took study drug and had at least one post-baseline efficacy assessment comprised the FAS.</population>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="115"/>
                <count group_id="O2" value="118"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.5" spread="7.7"/>
                    <measurement group_id="O2" value="-1.2" spread="8.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Null hypothesis: There is no difference between the two treatment management strategies in the mean change from baseline in diastolic blood pressure at Week 4.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&gt; 0.999</p_value>
            <p_value_desc>No adjustment for p-value for secondary analyses</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Difference in LS Means</param_type>
            <param_value>-0.00</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-2.01</ci_lower_limit>
            <ci_upper_limit>2.01</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Week 4 in Pulse Rate</title>
        <description>Mean at observation minus mean at baseline measured in beats per minute (bpm).</description>
        <time_frame>Week 4, baseline</time_frame>
        <population>Full analysis set (FAS). All randomized subjects who took study drug and had at least one post-baseline efficacy assessment comprised the FAS.</population>
        <group_list>
          <group group_id="O1">
            <title>Norvasc + TLC</title>
            <description>Blinded Norvasc (amlodipine) 5 to 10 milligram (mg) and matching Caduet placebo dosed once daily along with Therapeutic Lifestyle Changes (TLC) for 6 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Caduet + TLC</title>
            <description>Blinded Caduet (amlodipine besylate/atorvastatin calcium) 5/20 to 10/20 mg and matching Norvasc placebo dosed once daily along with TLC for 6 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Week 4 in Pulse Rate</title>
          <description>Mean at observation minus mean at baseline measured in beats per minute (bpm).</description>
          <population>Full analysis set (FAS). All randomized subjects who took study drug and had at least one post-baseline efficacy assessment comprised the FAS.</population>
          <units>bpm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="115"/>
                <count group_id="O2" value="118"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.1" spread="8.2"/>
                    <measurement group_id="O2" value="-0.9" spread="8.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Null hypothesis: There is no difference between the two treatment management strategies in the mean change from baseline in pulse rate at Week 4.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.363</p_value>
            <method>ANCOVA</method>
            <param_type>Difference in LS Means</param_type>
            <param_value>-0.90</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-2.83</ci_lower_limit>
            <ci_upper_limit>1.04</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Week 6 in Systolic Blood Pressure (SBP)</title>
        <description>Mean change at observation minus mean baseline.</description>
        <time_frame>Week 6, baseline</time_frame>
        <population>Full analysis set: all randomized subjects who take at least one dose of study drug and have any post-baseline efficacy assessments.</population>
        <group_list>
          <group group_id="O1">
            <title>Norvasc + TLC</title>
            <description>Blinded Norvasc (amlodipine) 5 to 10 milligram (mg) and matching Caduet placebo dosed once daily along with Therapeutic Lifestyle Changes (TLC) for 6 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Caduet + TLC</title>
            <description>Blinded Caduet (amlodipine besylate/atorvastatin calcium) 5/20 to 10/20 mg and matching Norvasc placebo dosed once daily along with TLC for 6 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Week 6 in Systolic Blood Pressure (SBP)</title>
          <description>Mean change at observation minus mean baseline.</description>
          <population>Full analysis set: all randomized subjects who take at least one dose of study drug and have any post-baseline efficacy assessments.</population>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="115"/>
                <count group_id="O2" value="118"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.0" spread="12.6"/>
                    <measurement group_id="O2" value="-4.0" spread="11.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Null hypothesis: There is no difference between the two treatment management strategies in the mean change from baseline in systolic blood pressure at Week 6.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.020</p_value>
            <p_value_desc>No adjustment for p-value for secondary analyses</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Difference in LS means</param_type>
            <param_value>-3.25</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-5.99</ci_lower_limit>
            <ci_upper_limit>-0.51</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Week 6 in Diastolic Blood Pressue (DBP)</title>
        <description>Change from mean at observation minus mean at baseline</description>
        <time_frame>Week 6, baseline</time_frame>
        <population>Full analysis set (FAS). All randomized subjects who took study drug and had at least one post-baseline efficacy assessment comprised the FAS.</population>
        <group_list>
          <group group_id="O1">
            <title>Norvasc + TLC</title>
            <description>Blinded Norvasc (amlodipine) 5 to 10 milligram (mg) and matching Caduet placebo dosed once daily along with Therapeutic Lifestyle Changes (TLC) for 6 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Caduet + TLC</title>
            <description>Blinded Caduet (amlodipine besylate/atorvastatin calcium) 5/20 to 10/20 mg and matching Norvasc placebo dosed once daily along with TLC for 6 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Week 6 in Diastolic Blood Pressue (DBP)</title>
          <description>Change from mean at observation minus mean at baseline</description>
          <population>Full analysis set (FAS). All randomized subjects who took study drug and had at least one post-baseline efficacy assessment comprised the FAS.</population>
          <units>mmHg</units>
          <param>Median</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="115"/>
                <count group_id="O2" value="118"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.1" spread="7.1"/>
                    <measurement group_id="O2" value="-1.7" spread="8.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Null hypothesis: There is no difference between the two treatment management strategies in the mean change from baseline in diastolic blood pressure at Week 6.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.351</p_value>
            <p_value_desc>No adjustment for p-value for secondary analyses</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Difference in LS Means</param_type>
            <param_value>-0.87</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-2.71</ci_lower_limit>
            <ci_upper_limit>0.97</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Week 6 in Pulse Rate</title>
        <description>Mean at observation minus mean at baseline</description>
        <time_frame>Week 6, baseline</time_frame>
        <population>Full analysis set (FAS). All randomized subjects who took study drug and had at least one post-baseline efficacy assessment comprised the FAS.</population>
        <group_list>
          <group group_id="O1">
            <title>Norvasc + TLC</title>
            <description>Blinded Norvasc (amlodipine) 5 to 10 milligram (mg) and matching Caduet placebo dosed once daily along with Therapeutic Lifestyle Changes (TLC) for 6 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Caduet + TLC</title>
            <description>Blinded Caduet (amlodipine besylate/atorvastatin calcium) 5/20 to 10/20 mg and matching Norvasc placebo dosed once daily along with TLC for 6 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Week 6 in Pulse Rate</title>
          <description>Mean at observation minus mean at baseline</description>
          <population>Full analysis set (FAS). All randomized subjects who took study drug and had at least one post-baseline efficacy assessment comprised the FAS.</population>
          <units>bpm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="115"/>
                <count group_id="O2" value="118"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.9" spread="8.1"/>
                    <measurement group_id="O2" value="1.1" spread="9.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Null hypothesis: There is no difference between the two treatment management strategies in mean change from baseline in pulse rate at Week 6.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.922</p_value>
            <p_value_desc>No adjustment for p-value for secondary analyses</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Difference in LS Means</param_type>
            <param_value>0.10</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-1.91</ci_lower_limit>
            <ci_upper_limit>2.11</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in LDL at Week 4.</title>
        <description>Change: mean of observation minus mean at baseline.</description>
        <time_frame>Week 4, baseline</time_frame>
        <population>Full analysis set (FAS) All randomized subjects who take at least one dose of study drug and have any post-baseline efficacy assessments.</population>
        <group_list>
          <group group_id="O1">
            <title>Norvasc + TLC</title>
            <description>Blinded Norvasc (amlodipine) 5 to 10 milligram (mg) and matching Caduet placebo dosed once daily along with Therapeutic Lifestyle Changes (TLC) for 6 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Caduet + TLC</title>
            <description>Blinded Caduet (amlodipine besylate/atorvastatin calcium) 5/20 to 10/20 mg and matching Norvasc placebo dosed once daily along with TLC for 6 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in LDL at Week 4.</title>
          <description>Change: mean of observation minus mean at baseline.</description>
          <population>Full analysis set (FAS) All randomized subjects who take at least one dose of study drug and have any post-baseline efficacy assessments.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="115"/>
                <count group_id="O2" value="118"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.5" spread="23.0"/>
                    <measurement group_id="O2" value="-47.8" spread="24.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Null hypothesis: There is no difference between the two treatment management strategies in the mean change from baseline in LDL at Week 4.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>No adjustment for p-value for secondary analyses</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Difference in LS Means</param_type>
            <param_value>-49.30</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-54.68</ci_lower_limit>
            <ci_upper_limit>-43.91</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in High Density Lipoprotein (HDL) at Week 4.</title>
        <description>Mean change at observation minus baseline.</description>
        <time_frame>Week 4, baseline</time_frame>
        <population>Full analysis set (FAS) All randomized subjects who take at least one dose of study drug and have any post-baseline efficacy assessments.</population>
        <group_list>
          <group group_id="O1">
            <title>Norvasc + TLC</title>
            <description>Blinded Norvasc (amlodipine) 5 to 10 milligram (mg) and matching Caduet placebo dosed once daily along with Therapeutic Lifestyle Changes (TLC) for 6 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Caduet + TLC</title>
            <description>Blinded Caduet (amlodipine besylate/atorvastatin calcium) 5/20 to 10/20 mg and matching Norvasc placebo dosed once daily along with TLC for 6 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in High Density Lipoprotein (HDL) at Week 4.</title>
          <description>Mean change at observation minus baseline.</description>
          <population>Full analysis set (FAS) All randomized subjects who take at least one dose of study drug and have any post-baseline efficacy assessments.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="115"/>
                <count group_id="O2" value="118"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.6" spread="5.8"/>
                    <measurement group_id="O2" value="0.6" spread="8.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Null hypothesis: There is no difference between the two treatment management strategies in the mean change from baseline in HDL at Week 4.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.739</p_value>
            <p_value_desc>No adjustment for p-value for secondary analyses</p_value_desc>
            <method>ANCOVA</method>
            <param_type>difference in LS Means</param_type>
            <param_value>-0.30</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-2.07</ci_lower_limit>
            <ci_upper_limit>1.47</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Total Cholesterol (TC) From Baseline to Week 4.</title>
        <description>Mean change at observation minus baseline.</description>
        <time_frame>Week 4, baseline</time_frame>
        <population>Full analysis set (FAS). All randomized subjects who took study drug and had at least one post-baseline efficacy assessment comprised the FAS.</population>
        <group_list>
          <group group_id="O1">
            <title>Norvasc + TLC</title>
            <description>Blinded Norvasc (amlodipine) 5 to 10 milligram (mg) and matching Caduet placebo dosed once daily along with Therapeutic Lifestyle Changes (TLC) for 6 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Caduet + TLC</title>
            <description>Blinded Caduet (amlodipine besylate/atorvastatin calcium) 5/20 to 10/20 mg and matching Norvasc placebo dosed once daily along with TLC for 6 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Total Cholesterol (TC) From Baseline to Week 4.</title>
          <description>Mean change at observation minus baseline.</description>
          <population>Full analysis set (FAS). All randomized subjects who took study drug and had at least one post-baseline efficacy assessment comprised the FAS.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="115"/>
                <count group_id="O2" value="118"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5" spread="23.5"/>
                    <measurement group_id="O2" value="-55.9" spread="26.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Null hypothesis: There is no difference between the two treatment management strategies in the mean change from baseline in TC at Week 4.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>No adjustment for p-value for secondary analyses</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Difference in LS Means</param_type>
            <param_value>-57.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-64.02</ci_lower_limit>
            <ci_upper_limit>51.81</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Triglycerides (TG) to Week 4.</title>
        <description>Mean change at observation minus baseline</description>
        <time_frame>Week 4, baseline</time_frame>
        <population>Full analysis set (FAS). All randomized subjects who took study drug and had at least one post-baseline efficacy assessment comprised the FAS.</population>
        <group_list>
          <group group_id="O1">
            <title>Norvasc + TLC</title>
            <description>Blinded Norvasc (amlodipine) 5 to 10 milligram (mg) and matching Caduet placebo dosed once daily along with Therapeutic Lifestyle Changes (TLC) for 6 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Caduet + TLC</title>
            <description>Blinded Caduet (amlodipine besylate/atorvastatin calcium) 5/20 to 10/20 mg and matching Norvasc placebo dosed once daily along with TLC for 6 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Triglycerides (TG) to Week 4.</title>
          <description>Mean change at observation minus baseline</description>
          <population>Full analysis set (FAS). All randomized subjects who took study drug and had at least one post-baseline efficacy assessment comprised the FAS.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="115"/>
                <count group_id="O2" value="118"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.4" spread="73.2"/>
                    <measurement group_id="O2" value="-45.7" spread="62.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Null hypothesis: There is no difference between the two treatment management strategies in the mean change from baseline in TG at Week 4.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>No adjustment for p-value for secondary analyses</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Difference in LS Means</param_type>
            <param_value>-47.27</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-63.37</ci_lower_limit>
            <ci_upper_limit>-31.16</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in LDL at Week 6.</title>
        <description>Mean change at observation minus baseline.</description>
        <time_frame>Week 6, baseline</time_frame>
        <population>Full analysis set. All randomized subjects who took study drug and had at least one post-baseline efficacy assessment comprised the FAS.</population>
        <group_list>
          <group group_id="O1">
            <title>Norvasc + TLC</title>
            <description>Blinded Norvasc (amlodipine) 5 to 10 milligram (mg) and matching Caduet placebo dosed once daily along with Therapeutic Lifestyle Changes (TLC) for 6 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Caduet + TLC</title>
            <description>Blinded Caduet (amlodipine besylate/atorvastatin calcium) 5/20 to 10/20 mg and matching Norvasc placebo dosed once daily along with TLC for 6 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in LDL at Week 6.</title>
          <description>Mean change at observation minus baseline.</description>
          <population>Full analysis set. All randomized subjects who took study drug and had at least one post-baseline efficacy assessment comprised the FAS.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="115"/>
                <count group_id="O2" value="118"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3" spread="24.8"/>
                    <measurement group_id="O2" value="-49.2" spread="24.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Null hypothesis: There is no difference between the two treatment management strategies in the mean change from baseline in LDL at Week 6.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>No adjustment for p-value for secondary analyses</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Difference in LS Means</param_type>
            <param_value>-51.21</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-56.88</ci_lower_limit>
            <ci_upper_limit>-45.55</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in HDL at Week 6.</title>
        <description>Mean change at observation minus baseline.</description>
        <time_frame>Week 6, baseline</time_frame>
        <population>Full analysis set (FAS). All randomized subjects who took study drug and had at least one post-baseline efficacy assessment comprised the FAS.</population>
        <group_list>
          <group group_id="O1">
            <title>Norvasc + TLC</title>
            <description>Blinded Norvasc (amlodipine) 5 to 10 milligram (mg) and matching Caduet placebo dosed once daily along with Therapeutic Lifestyle Changes (TLC) for 6 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Caduet + TLC</title>
            <description>Blinded Caduet (amlodipine besylate/atorvastatin calcium) 5/20 to 10/20 mg and matching Norvasc placebo dosed once daily along with TLC for 6 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in HDL at Week 6.</title>
          <description>Mean change at observation minus baseline.</description>
          <population>Full analysis set (FAS). All randomized subjects who took study drug and had at least one post-baseline efficacy assessment comprised the FAS.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="115"/>
                <count group_id="O2" value="118"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.2" spread="8.2"/>
                    <measurement group_id="O2" value="0.4" spread="8.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Null hypothesis: There is no difference between the two treatment management strategies in the mean change from baseline in HDL at Week 6.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.329</p_value>
            <p_value_desc>No adjustment for p-value for secondary analyses</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Difference in LS Means</param_type>
            <param_value>-1.02</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-3.07</ci_lower_limit>
            <ci_upper_limit>1.03</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Total Cholesterol (TC) to Week 6.</title>
        <description>Mean change at observation minus baseline.</description>
        <time_frame>Week 6, baseline</time_frame>
        <population>Full analysis set (FAS) All randomized subjects who take at least one dose of study drug and have any post-baseline efficacy assessments.</population>
        <group_list>
          <group group_id="O1">
            <title>Norvasc + TLC</title>
            <description>Blinded Norvasc (amlodipine) 5 to 10 milligram (mg) and matching Caduet placebo dosed once daily along with Therapeutic Lifestyle Changes (TLC) for 6 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Caduet + TLC</title>
            <description>Blinded Caduet (amlodipine besylate/atorvastatin calcium) 5/20 to 10/20 mg and matching Norvasc placebo dosed once daily along with TLC for 6 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Total Cholesterol (TC) to Week 6.</title>
          <description>Mean change at observation minus baseline.</description>
          <population>Full analysis set (FAS) All randomized subjects who take at least one dose of study drug and have any post-baseline efficacy assessments.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="115"/>
                <count group_id="O2" value="118"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.7" spread="23.8"/>
                    <measurement group_id="O2" value="-56.8" spread="28.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Null hypothesis: There is no difference between the two treatment management strategies in the mean change from baseline in TC at Week 6.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>No adjustment for p-value for secondary analyses</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Difference in LS Means</param_type>
            <param_value>-62.07</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-68.49</ci_lower_limit>
            <ci_upper_limit>-55.65</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Triglycerides (TG) at Week 6.</title>
        <description>Mean change at observation minus mean baseline.</description>
        <time_frame>Week 6 , baseline</time_frame>
        <population>Full analysis set (FAS). All randomized subjects who took study drug and had at least one post-baseline efficacy assessment comprised the FAS.</population>
        <group_list>
          <group group_id="O1">
            <title>Norvasc + TLC</title>
            <description>Blinded Norvasc (amlodipine) 5 to 10 milligram (mg) and matching Caduet placebo dosed once daily along with Therapeutic Lifestyle Changes (TLC) for 6 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Caduet + TLC</title>
            <description>Blinded Caduet (amlodipine besylate/atorvastatin calcium) 5/20 to 10/20 mg and matching Norvasc placebo dosed once daily along with TLC for 6 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Triglycerides (TG) at Week 6.</title>
          <description>Mean change at observation minus mean baseline.</description>
          <population>Full analysis set (FAS). All randomized subjects who took study drug and had at least one post-baseline efficacy assessment comprised the FAS.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="115"/>
                <count group_id="O2" value="118"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.6" spread="115.3"/>
                    <measurement group_id="O2" value="-42.6" spread="67.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Null hypothesis: There is no difference between the two treatment management strategies in the mean change in TG from baseline in at Week 6.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>No adjustment for p-value for secondary analyses</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Difference in LS Means</param_type>
            <param_value>-53.95</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-77.61</ci_lower_limit>
            <ci_upper_limit>-30.29</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Week 4 in Framingham Predicted Absolute 10-year Risk.</title>
        <description>Framingham prediction of absolute 10-year risk of CHD outcomes (MI or CHD death) are calculations based on total point score (range less than negative 3 [best] to greater than or equal to 14 [worst] for men; less than or equal to negative 2 [best] and greater than or equal to 17 [worst] for women) of subject age, sex, current blood pressure treatment status, current smoking status, total cholesterol, high-density lipoprotein cholesterol and systolic blood pressure calculated at Week 4. Mean at observation minus mean at baseline.</description>
        <time_frame>Week 4, baseline</time_frame>
        <population>Full analysis set (FAS). All randomized subjects who took study drug and had at least one post-baseline efficacy assessment comprised the FAS.</population>
        <group_list>
          <group group_id="O1">
            <title>Norvasc + TLC</title>
            <description>Blinded Norvasc (amlodipine) 5 to 10 milligram (mg) and matching Caduet placebo dosed once daily along with Therapeutic Lifestyle Changes (TLC) for 6 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Caduet + TLC</title>
            <description>Blinded Caduet (amlodipine besylate/atorvastatin calcium) 5/20 to 10/20 mg and matching Norvasc placebo dosed once daily along with TLC for 6 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Week 4 in Framingham Predicted Absolute 10-year Risk.</title>
          <description>Framingham prediction of absolute 10-year risk of CHD outcomes (MI or CHD death) are calculations based on total point score (range less than negative 3 [best] to greater than or equal to 14 [worst] for men; less than or equal to negative 2 [best] and greater than or equal to 17 [worst] for women) of subject age, sex, current blood pressure treatment status, current smoking status, total cholesterol, high-density lipoprotein cholesterol and systolic blood pressure calculated at Week 4. Mean at observation minus mean at baseline.</description>
          <population>Full analysis set (FAS). All randomized subjects who took study drug and had at least one post-baseline efficacy assessment comprised the FAS.</population>
          <units>score on scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="115"/>
                <count group_id="O2" value="118"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.3" spread="2.5"/>
                    <measurement group_id="O2" value="-2.8" spread="3.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Null hypothesis: There is no difference between the two treatment management strategies in mean change from baseline to Week 4 in Framingham predicted absolute 10-year risk.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>No adjustment for p-value for secondary analyses</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Difference in LS Means</param_type>
            <param_value>-2.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-3.1</ci_lower_limit>
            <ci_upper_limit>-1.7</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline to Week 6 in Framingham Predicted Absolute 10-year Risk</title>
        <description>Framingham prediction of absolute 10-year risk of Coronary Heart Disease (CHD) outcomes (myocardial infarction [MI] or CHD death) are calculations based on total point score (range less than negative 3 [best] to greater than or equal to 14 [worst] for men; less than or equal to negative 2 [best] and greater than or equal to 17 [worst] for women) of subject age, sex, current blood pressure treatment status, current smoking status, total cholesterol, high-density lipoprotein cholesterol, and systolic blood pressure calculated at Week 6. Mean at observation minus mean at baseline.</description>
        <time_frame>Week 6, baseline</time_frame>
        <population>The full analysis set of all randomized subjects who took at least one dose of study drug and had any post-baseline efficacy assessment</population>
        <group_list>
          <group group_id="O1">
            <title>Norvasc + TLC</title>
            <description>Blinded Norvasc (amlodipine) 5 to 10 milligram (mg) and matching Caduet placebo dosed once daily along with Therapeutic Lifestyle Changes (TLC) for 6 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Caduet + TLC</title>
            <description>Blinded Caduet (amlodipine besylate/atorvastatin calcium) 5/20 to 10/20 mg and matching Norvasc placebo dosed once daily along with TLC for 6 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Week 6 in Framingham Predicted Absolute 10-year Risk</title>
          <description>Framingham prediction of absolute 10-year risk of Coronary Heart Disease (CHD) outcomes (myocardial infarction [MI] or CHD death) are calculations based on total point score (range less than negative 3 [best] to greater than or equal to 14 [worst] for men; less than or equal to negative 2 [best] and greater than or equal to 17 [worst] for women) of subject age, sex, current blood pressure treatment status, current smoking status, total cholesterol, high-density lipoprotein cholesterol, and systolic blood pressure calculated at Week 6. Mean at observation minus mean at baseline.</description>
          <population>The full analysis set of all randomized subjects who took at least one dose of study drug and had any post-baseline efficacy assessment</population>
          <units>score on scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="115"/>
                <count group_id="O2" value="118"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.1" spread="2.9"/>
                    <measurement group_id="O2" value="-2.9" spread="3.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Null hypothesis: There is no difference between the two treatment management strategies in the mean change from baseline to Week 6 in Framingham predicted absolute 10-year risk.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>No adjustment for p-value for secondary analyses</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Difference in LS Means</param_type>
            <param_value>-2.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-3.5</ci_lower_limit>
            <ci_upper_limit>-2.1</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Norvasc + TLC</title>
          <description>Blinded Norvasc (amlodipine) 5 to 10 milligram (mg) and matching Caduet placebo dosed once daily along with Therapeutic Lifestyle Changes (TLC) for 6 weeks.</description>
        </group>
        <group group_id="E2">
          <title>Caduet + TLC</title>
          <description>Blinded Caduet (amlodipine besylate/atorvastatin calcium) 5/20 to 10/20 mg and matching Norvasc placebo dosed once daily along with TLC for 6 weeks.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="122"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>2</frequency_threshold>
        <default_vocab>MedDRA v11.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="122"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="122"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="122"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="122"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="122"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="122"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="122"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="122"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Pfizer has the right to review disclosures, requesting a delay of &lt; 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), &lt; 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential info other than study results.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Pfizer ClinicalTrials.gov Call Center</name_or_title>
      <organization>Pfizer, Inc.</organization>
      <phone>1-800-718-1021</phone>
      <email>ClinicalTrials.govCallCenter@pfizer.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

